AVECRIS

About:

AVECRIS is addressing one of gene therapy's most difficult challenges: long-lasting, cell-type-specific expression.

Top Investors: First Flight Venture Center, Alameda Research

Description:

AVECRIS platform extends the capabilities of mRNA / RNA approaches. AVECRIS provides the following services: cell-type specific gene expression / Protein expression that is stable and long-lasting / Non-integrating, unlikely to elicit innate immunity / Redosable and titratable / Unprecedented ability to deliver mitochondrial gene therapy / A DNA-based backbone construct that is universal, unmodified, and has a modular coding region that allows for rapid and infinite application programming / Manufacturing that is quick, dependable, highly scalable, and low-cost.

Total Funding Amount:

$3.61M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Singapore, Central Region, Singapore

Founded Date:

2017-01-01

Contact Email:

info(AT)avecris.com

Founders:

Number of Employees:

1-10

Last Funding Date:

2022-08-10

IPO Status:

Private

Industries: